Pacira Pharmaceuticals, Inc. Reports First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Mizuho Securities Cuts Price Target on Pacira Pharma (PCRX); Sights Conservatism
May 3, 2016 7:22 AM EDTMizuho Securities maintained a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and cut the price target to $64.00 (from $79.00), following the company's 1Q earnings report. PCRX reported revenues of $65.5M and an adjusted EPS of $0.14 vs. the consensus estimates of $66.9M and $0.07. There was... More
Pacira Pharma (PCRX) Tops Q1 EPS by 8c; EXPAREL Sales Rose 14%
May 2, 2016 8:57 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q1 EPS of $0.15, $0.08 better than the analyst estimate of $0.07. Revenue for the quarter came in at $65.5 million versus the consensus estimate of $67.11 million.
EXPAREL net product revenues were $63.8 million in the first quarter of 2016, compared to $56.0 million in... More
